drugset / Trial / NCT00416403

Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

NCT00416403

RandomizedParallel-groupSingle-blindTreatment

Summary

RATIONALE: Collecting samples of blood and tissue from patients with cancer to study in the laboratory may help doctors learn how fluvastatin effects biomarkers related to breast cancer. PURPOSE: This randomized phase II trial is studying how fluvastatin effects biomarkers in women undergoing surgery for ductal carcinoma in situ or stage I breast cancer.

Timeline

Start
2006-07
Primary completion
2007-09
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluvastatin Other / unclassified 20 mg Oral
Subject Fluvastatin Other / unclassified 80 mg Oral

Indications